Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
Edesa Biotech, a clinical-stage biopharmaceutical company, has announced its upcoming participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference. The event is scheduled to take place in Toronto, Ontario on May 5-6, 2025.
Key Details:
- Presentation Date: Monday, May 5, 2025
- Time: 4:00 PM Eastern Time
- Location: Toronto, Ontario
The company, which specializes in developing host-directed therapeutics for immuno-inflammatory diseases, has made its management team available for meetings during the conference. Interested parties can schedule meetings through either the conference's online portal or by directly contacting Edesa at investors@edesabiotech.com.
Edesa Biotech, un'azienda biofarmaceutica in fase clinica, ha annunciato la sua prossima partecipazione alla Conferenza per Investitori nel Settore Sanitario 2024 di Bloom Burton & Co. L'evento si terrà a Toronto, Ontario, il 5 e 6 maggio 2025.
Dettagli principali:
- Data della presentazione: lunedì 5 maggio 2025
- Orario: 16:00 ora orientale
- Luogo: Toronto, Ontario
L'azienda, specializzata nello sviluppo di terapie dirette all'ospite per malattie immuno-infiammatorie, ha reso disponibile il suo team di gestione per incontri durante la conferenza. Gli interessati possono prenotare un incontro tramite il portale online della conferenza o contattando direttamente Edesa all'indirizzo investors@edesabiotech.com.
Edesa Biotech, una empresa biofarmacéutica en etapa clínica, ha anunciado su próxima participación en la Conferencia de Inversores en Salud 2024 de Bloom Burton & Co. El evento se llevará a cabo en Toronto, Ontario, los días 5 y 6 de mayo de 2025.
Detalles clave:
- Fecha de la presentación: lunes 5 de mayo de 2025
- Hora: 4:00 PM hora del Este
- Ubicación: Toronto, Ontario
La compañía, especializada en el desarrollo de terapéuticas dirigidas al huésped para enfermedades inmunoinflamatorias, ha puesto a disposición de los asistentes a su equipo directivo para reuniones durante la conferencia. Los interesados pueden agendar citas a través del portal en línea de la conferencia o contactando directamente a Edesa en investors@edesabiotech.com.
에데사 바이오텍은 임상 단계의 바이오제약 회사로서, 2024 블룸 버튼 & 컴퍼니 헬스케어 투자자 컨퍼런스에 참가할 예정임을 발표했습니다. 이 행사는 2025년 5월 5일부터 6일까지 온타리오주 토론토에서 개최됩니다.
주요 정보:
- 발표일: 2025년 5월 5일 월요일
- 시간: 동부 표준시 오후 4시
- 장소: 온타리오주 토론토
면역 염증 질환을 위한 숙주 지향 치료제 개발을 전문으로 하는 이 회사는 컨퍼런스 기간 동안 경영진과의 미팅을 제공합니다. 관심 있는 분들은 컨퍼런스 온라인 포털을 통해 또는 investors@edesabiotech.com으로 직접 연락하여 미팅을 예약할 수 있습니다.
Edesa Biotech, une entreprise biopharmaceutique en phase clinique, a annoncé sa prochaine participation à la Conférence des investisseurs en santé 2024 de Bloom Burton & Co. L'événement se tiendra à Toronto, Ontario, les 5 et 6 mai 2025.
Détails clés :
- Date de la présentation : lundi 5 mai 2025
- Heure : 16h00 heure de l'Est
- Lieu : Toronto, Ontario
L'entreprise, spécialisée dans le développement de thérapeutiques dirigées contre l'hôte pour les maladies immuno-inflammatoires, met à disposition son équipe de direction pour des réunions durant la conférence. Les personnes intéressées peuvent planifier des rendez-vous via le portail en ligne de la conférence ou en contactant directement Edesa à investors@edesabiotech.com.
Edesa Biotech, ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, hat seine bevorstehende Teilnahme an der Bloom Burton & Co. Healthcare Investor Conference 2024 angekündigt. Die Veranstaltung findet am 5. und 6. Mai 2025 in Toronto, Ontario, statt.
Wichtige Details:
- Präsentationstermin: Montag, 5. Mai 2025
- Uhrzeit: 16:00 Uhr Eastern Time
- Ort: Toronto, Ontario
Das Unternehmen, das sich auf die Entwicklung von wirtsgerichteten Therapeutika für immun-entzündliche Erkrankungen spezialisiert hat, stellt sein Management-Team für Treffen während der Konferenz zur Verfügung. Interessenten können Termine entweder über das Online-Portal der Konferenz oder direkt per E-Mail an investors@edesabiotech.com vereinbaren.
- Company secured participation in a major healthcare investor conference, potentially increasing visibility with investors
- None.
TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for May 5-6 2025 in Toronto, Ontario.
Edesa management is scheduled to present on Monday, May 5 at 4:00pm ET. To meet with Edesa during the conference, please utilize the conference’s online portal or contact the company directly at investors@edesabiotech.com.
About Edesa Biotech
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (
Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
Contact
Gary Koppenjan
Edesa Biotech, Inc.
investors@edesabiotech.com
FAQ
When is Edesa Biotech (NASDAQ:EDSA) presenting at the 2025 Bloom Burton Healthcare Conference?
How can investors meet with Edesa Biotech (NASDAQ:EDSA) at the 2025 Bloom Burton Conference?
What type of company is Edesa Biotech (NASDAQ:EDSA)?
Where is the 2025 Bloom Burton Healthcare Conference being held?
What therapeutic focus does Edesa Biotech (NASDAQ:EDSA) have?
